Palisade Bio Inc
PALI
查看详细走势图
1.830USD
+0.160+9.58%
收盘 12/19, 16:00（美东）报价延迟15分钟
16.69M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.58%
5天
-5.67%
1月
-21.79%
6月
+196.45%
今年开始到现在
+10.91%
1年
+4.57%
查看详细走势图
TradingKey Palisade Bio Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Palisade Bio Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名182/404位。机构持股占比非常低，近一月多位分析师给出公司评级为买入。最高目标价11.67。中期看，股价处于上升通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Palisade Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
11.667
目标均价
+544.57%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Palisade Bio Inc亮点
亮点风险
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
估值低估
公司最新PE估值-0.88，处于3年历史低位
机构减仓
最新机构持股87.73K股，环比减少77.67%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值62.11K
活跃度增加
近期活跃度增加，过去20天平均换手率0.49
Palisade Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Palisade Bio Inc简介
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
公司代码PALI
公司Palisade Bio Inc
CEOFinley (J. D.)
网址https://palisadebio.com/
常见问题
Palisade Bio Inc(PALI)的当前股价是多少？
Palisade Bio Inc(PALI)的当前股价是 1.830。
Palisade Bio Inc的股票代码是什么？
Palisade Bio Inc的股票代码是PALI。
Palisade Bio Inc股票的52周最高点是多少？
Palisade Bio Inc股票的52周最高点是2.590。
Palisade Bio Inc股票的52周最低点是多少？
Palisade Bio Inc股票的52周最低点是0.530。
Palisade Bio Inc的市值是多少？
Palisade Bio Inc的市值是16.69M。
Palisade Bio Inc的净利润是多少？
Palisade Bio Inc的净利润为-14.44M。
现在Palisade Bio Inc(PALI)的股票是买入、持有还是卖出？
根据分析师评级，Palisade Bio Inc(PALI)的总体评级为买入，目标价格为11.667。
Palisade Bio Inc(PALI)股票的每股收益（EPS TTM）是多少
Palisade Bio Inc(PALI)股票的每股收益（EPS TTM）是-2.079。
相关品种
